Cargando…
SZN-413, a FZD4 Agonist, as a Potential Novel Therapeutic for the Treatment of Diabetic Retinopathy
PURPOSE: There remains a high unmet need for therapies with new mechanisms of action to achieve reperfusion of ischemic retina in diabetic retinopathy. We examined whether a novel frizzled class receptor 4 (FZD4) agonist could promote regeneration of functional blood vessels in animal models of reti...
Autores principales: | Nguyen, Huy, Chen, Hui, Vuppalapaty, Meghah, Whisler, Elizabeth, Logas, Kelsey Ronarda, Sampathkumar, Parthasarathy, Fletcher, Russell Byron, Sura, Asmiti, Suen, Nicholas, Gupta, Suhani, Lopez, Tom, Ye, Jay, Tu, Shengjiang, Bolaki, Menaka, Yeh, Wen-Chen, Li, Yang, Lee, Sung-Jin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Association for Research in Vision and Ophthalmology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520515/ https://www.ncbi.nlm.nih.gov/pubmed/36149648 http://dx.doi.org/10.1167/tvst.11.9.19 |
Ejemplares similares
-
Erratum in: SZN-413, a FZD4 Agonist, as a Potential Novel Therapeutic for the Treatment of Diabetic Retinopathy
Publicado: (2022) -
Therapeutic blood-brain barrier modulation and stroke treatment by a bioengineered FZD(4)-selective WNT surrogate in mice
por: Ding, Jie, et al.
Publicado: (2023) -
FZD4 in a Large Chinese Population With Familial Exudative Vitreoretinopathy: Molecular Characteristics and Clinical Manifestations
por: Lu, Jinglin, et al.
Publicado: (2022) -
Robust Colonic Epithelial Regeneration and Amelioration of Colitis via FZD-Specific Activation of Wnt Signaling
por: Xie, Liqin, et al.
Publicado: (2022) -
Measuring the Contributions of Basal Laminar Deposit and Bruch's Membrane in Age-Related Macular Degeneration
por: Sura, Amol A., et al.
Publicado: (2020)